Rheumatoid Arthritis & Insurance

Life Insurance With
Rheumatoid Arthritis

Joint-only RA with good disease control often qualifies for standard rates. Systemic complications and biologics shift the picture. Here's the complete underwriting breakdown.

📅 Updated November 2026⏱️ 10 min read🧬 HLA-DRB1 genetics section
🧬
Reviewed by the DNAPolicy.org Editorial Team
Our life insurance guides are reviewed for accuracy by licensed insurance professionals and cross-referenced with current underwriting guidelines. Content is updated regularly to reflect industry changes. Last reviewed: November 2026

The Key Distinction

✅ Joint-only RA
Well-controlled inflammation, no organ damage, managed with DMARDs. Standard to Table B at most carriers. This is the majority of RA patients.
⚠️ Systemic RA
Pulmonary fibrosis, cardiovascular involvement, kidney disease, or other organ damage. Changes underwriting significantly — table-rated to possible decline.

RA Insurance Impact Tool

Enter your RA profile to see your underwriting outlook and estimated rate.

Est. monthly ($500K / 20yr term)
$53/mo
Comparison (healthy non-smoker, same age)
$48/mo
Underwriting outlook
Mild RA on methotrexate or hydroxychloroquine with good control. Standard to Table A at most carriers. Controlled inflammatory markers will help.

Estimates for healthy non-smoker baseline. Actual outcomes depend on complete medical records. Shop 3+ carriers.

RA Medications and What They Signal

MedicationClassUnderwriting SignalLab Concerns
Hydroxychloroquine (Plaquenil)Antimalarial DMARD✅ Favorable — first-line, mild diseaseMinimal
Methotrexate (MTX)DMARD✅ Standard DMARD — signals moderate RA but controlledLiver enzymes (ALT/AST) — monitor
Leflunomide (Arava)DMARD⚠️ Similar to MTX — hepatotoxic potentialLiver enzymes
SulfasalazineDMARD✅ Well-tolerated — moderate RA signalCBC (can affect white cells)
Adalimumab (Humira)TNF inhibitor (biologic)⚠️ Moderate-severe disease signalCBC, infection risk noted
Etanercept (Enbrel)TNF inhibitor (biologic)⚠️ Moderate-severe disease signalCBC, infection risk noted
Tocilizumab (Actemra)IL-6 inhibitor (biologic)⚠️ Often used after TNF failure — signals harder-to-treat RACBC, liver enzymes, lipids
Tofacitinib (Xeljanz)JAK inhibitor⚠️ Newer class — FDA warnings on cardiovascular/cancer riskCBC, lipids, liver enzymes
Prednisone (long-term)Corticosteroid⚠️ Signals poorly controlled disease; glucose/BP effectsGlucose, HbA1c, blood pressure

The Genetics of Rheumatoid Arthritis

RA has one of the strongest genetic signatures of any autoimmune disease — genetics account for approximately 50–60% of disease risk. The major genetic factors:

HLA-DRB1
Major Histocompatibility Complex
The "shared epitope" in HLA-DRB1 alleles is the strongest genetic risk factor for RA — present in ~70% of RA patients vs. ~30% of the general population. DRB1*04:01 and *04:04 are highest risk. Associated with anti-CCP positivity and more erosive, severe disease.
PTPN22
Protein tyrosine phosphatase N22
The R620W variant (rs2476601) is one of the strongest non-HLA RA risk variants. Affects T-cell and B-cell signaling. Doubles the risk of RA in carriers. Also associated with other autoimmune diseases (Type 1 diabetes, lupus, thyroid disease).
STAT4
Signal transducer and activator of transcription 4
Involved in cytokine signaling (IL-12, interferon). Variants are associated with RA risk and are found across multiple autoimmune conditions. The rs7574865 variant increases RA risk by ~20–30% in carriers.
CTLA4
Cytotoxic T-lymphocyte-associated protein 4
Regulates T-cell activation. Variants are associated with RA and other autoimmune diseases. Notably, abatacept (Orencia) — a biologic RA treatment — works by targeting the CTLA4 pathway, making this gene clinically relevant.
Insurance implications: Life insurers underwrite RA based on clinical markers (CRP, ESR, RF, anti-CCP, disease activity) and organ function — not HLA genotype or other genetic variants. Having the HLA-DRB1 shared epitope has no direct underwriting impact. GINA and life insurance →

What Underwriters Evaluate for RA

Disease activity
Controlled inflammation (normal CRP, ESR) = best outcome. Active disease = higher table rating.
Medication class
NSAIDs → methotrexate → biologics → JAK inhibitors signals increasing severity.
Inflammatory markers
CRP, ESR, RF titer, anti-CCP levels from blood work. High titers = more severe disease signal.
Organ involvement
Pulmonary (ILD/fibrosis), cardiac (vasculitis, pericarditis), kidney. Any systemic involvement = more cautious underwriting.
Liver function
Methotrexate and leflunomide can elevate ALT/AST. Elevated levels will be noted and may prompt review.
Functional status
Still working and active? Positive underwriting signal. Disability or significant functional impairment = negative.

Have Osteoarthritis, Not Rheumatoid Arthritis?

Osteoarthritis is a degenerative joint condition — not an autoimmune disease. Life insurance underwriters typically view OA as a minimal risk factor that rarely affects premiums. If you have OA and arrived here searching for life insurance with arthritis, you likely have significantly more favorable options than this page suggests. Standard rates are typically available for OA applicants.

Related Guides

Pre-Existing Conditions Hub →
12 conditions — the complete reference.
No-Exam Options →
May be favorable for managed RA.
High Blood Pressure + Insurance →
Chronic inflammation raises CV risk.
Genetic Testing + Insurance →
HLA and autoimmune genetics implications.

Frequently Asked Questions

Can I get life insurance with rheumatoid arthritis?
Yes — most people with rheumatoid arthritis can get life insurance. RA is a well-understood condition for life insurance underwriters, and many applicants with well-controlled RA qualify for standard or near-standard rates. The key factors are: disease activity (how well controlled), medications (which ones and for how long), and whether RA has caused systemic complications beyond the joints (pulmonary fibrosis, cardiovascular disease, kidney involvement). RA limited to joints with good disease control typically results in standard to Table B rates. Systemic involvement with organ damage creates a more challenging underwriting picture.
What is the difference between rheumatoid arthritis and osteoarthritis for life insurance?
This distinction matters significantly in underwriting. Osteoarthritis (OA) is a degenerative joint condition caused by wear and tear. It is not an autoimmune disease and does not typically affect life expectancy or cause systemic complications. Life insurance underwriters typically view OA as a minimal risk factor — it may not affect your rates at all. Rheumatoid arthritis (RA) is an autoimmune disease where the immune system attacks joint tissue. RA can cause systemic complications (cardiovascular, pulmonary, kidney) and requires disease-modifying medications. RA receives more careful underwriting scrutiny than OA. If you have OA and are worried, you likely have more favorable options than you think.
Do biologic medications affect my life insurance application?
Yes — but the impact is nuanced. Biologics (TNF inhibitors like adalimumab/Humira, etanercept/Enbrel; IL-6 inhibitors like tocilizumab/Actemra; JAK inhibitors like tofacitinib/Xeljanz) signal that your RA is moderate to severe — requiring more aggressive treatment than methotrexate alone. This typically moves you from Standard to Table A/B territory. However, the fact that you are on a biologic and your disease is controlled is viewed more favorably than uncontrolled RA on no disease-modifying treatment. The medication class signals severity; the disease control signals management. Some underwriters ask specifically whether you use biologics because they know what it means.
What systemic complications of RA affect life insurance most?
Rheumatoid arthritis can affect multiple organ systems, and each complication adds to the underwriting risk: Cardiovascular involvement (rheumatoid vasculitis, pericarditis, elevated CV risk from chronic inflammation): most significant for underwriting. Pulmonary involvement (interstitial lung disease, pulmonary fibrosis): significant, severity-dependent. Kidney involvement (amyloidosis, medication-related nephropathy): important — creatinine and GFR will be reviewed. Felty's syndrome (RA + enlarged spleen + low white cells): rare but serious. Rheumatoid nodules and eye involvement: typically less significant for underwriting. Underwriters will review inflammatory markers (CRP, ESR, RF, anti-CCP) alongside organ function tests.
What inflammatory markers do life insurance underwriters look at for RA?
During a fully underwritten medical exam, blood work will reveal key RA markers. Underwriters evaluate: Rheumatoid factor (RF): positive in ~70-80% of RA patients — high titers associated with more severe disease. Anti-CCP antibodies: highly specific to RA — high levels associated with more erosive disease. CRP (C-reactive protein) and ESR: markers of systemic inflammation — elevated levels indicate active disease. CBC: anemia of chronic disease is common in RA and may be noted. Liver and kidney function: important for methotrexate and NSAID users. Controlled inflammatory markers suggest well-managed disease and lead to better underwriting outcomes.
Is lupus (SLE) treated the same as RA for life insurance?
No — systemic lupus erythematosus (SLE) is generally underwritten more cautiously than RA. SLE has higher rates of serious organ involvement (lupus nephritis, CNS lupus, pericarditis) and is associated with higher mortality risk than RA. Many traditional carriers will table-rate or decline SLE applicants more readily than RA applicants. Mild SLE with no organ involvement may qualify for traditional coverage at some carriers, but this is more difficult than equivalent RA. If you have SLE rather than RA, work specifically with an impaired-risk broker who has experience placing SLE cases.
What is the HLA-DRB1 gene and why does it matter for RA?
HLA-DRB1 is the strongest genetic risk factor for rheumatoid arthritis. The "shared epitope" — specific amino acid sequences in HLA-DRB1 alleles (particularly DRB1*04:01, *04:04, *01:01) — is present in approximately 70% of RA patients but only 30% of the general population. The shared epitope is not just a risk factor for developing RA — it's associated with more severe, erosive disease and anti-CCP antibody positivity. Life insurance underwriters evaluate RA based on clinical presentation, not HLA genotype — but HLA-DRB1 explains why some people's RA is more aggressive than others.
Can my RA medications cause problems during the life insurance medical exam?
Yes — some RA medications can affect lab results that life insurance underwriters evaluate. Methotrexate: can cause liver enzyme elevation (ALT/AST) — elevated liver enzymes will be noted and may prompt additional review. Leflunomide: also hepatotoxic — same liver enzyme concern. NSAIDs: can affect kidney function (creatinine/GFR) with long-term use. Corticosteroids (prednisone): elevated glucose or HbA1c if on regular steroids — may raise diabetes flags. Biologic agents: may affect CBC (some cause mild anemia or low white cell counts). Inform your exam nurse about all RA medications so results are interpreted in context. Some carriers allow physician-provided lab interpretation with the application.

Well-controlled RA shouldn't stand between you and coverage.

Shop multiple carriers, provide your inflammatory marker results, and document disease control. The right carrier makes a significant difference.

Calculate Your Coverage Need →All Conditions Guide →